Actualités et vidéos - UCB - Page 3

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF) PR Newswire ATLANTA, Nov. 11, 2023 A post hoc analysis from the EXXELERATE Phase 4 trial showed that 65.7 percent of CIMZIA-treated patients with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels achieved low disease activity at Week 104 1 CIMZIA maintained drug concentrations and achieved Low Disease Activity regardless of RF levels in...

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

• Long-term data on investigational bimekizumab in the treatment of adults with ankylosing spondylitis showed sustained improvements for up to five years with the safety profile consistent with previous observations

PR Newswire ATLANTA, Nov. 10, 2023 ATLANTA , Nov. 10, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new...

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session PR Newswire ATLANTA, Nov. 1, 2023 14 presentations – including 3 oral sessions – have been selected by AANEM and MGFA for inclusion across scientific programs Results presented across UCB's generalized myasthenia gravis (gMG) portfolio, including Open Label...

NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters PR Newswire ATLANTA, Oct. 31, 2023 Median time to return to full baseline function occurred within 90 minutes following outpatient treatment with NAYZILAM ® (midazolam) nasal spray, with a similar effect in those receiving either one or two doses Median time to return to full baseline function was stable over the course of...

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire ATLANTA, Oct. 18, 2023 BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis Approval is supported by three Phase 3 trials where bimekizumab consistently delivered fast, complete and lasting levels of skin clearance up to one year, and was generally well tolerated UCB expects...

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis PR Newswire ATLANTA, Oct. 17, 2023 FDA approval of ZILBRYSQ ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive 1 ZILBRYSQ is the first once-daily subcutaneous, targeted C5 complement inhibitor for gMG. It is the only once-daily gMG-target therapy for...

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 PR Newswire ATLANTA, Oct. 13, 2023 Results from the Phase 3 studies evaluating impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa will be shared in two oral presentations ATLANTA , Oct. 13, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS)...

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa PR Newswire ATLANTA, Oct. 12, 2023 Bimekizumab treatment resulted in clinically meaningful improvements in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR90 and HiSCR100 vs. placebo at Week 16, with improvements increasing for patients remaining in the study through Week 48 Over 8 in 10 patients treated with bimekizumab who achieved a HiSCR50 response...

UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. PR Newswire ATLANTA, July 21, 2023 RYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive...

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis PR Newswire ATLANTA, June 27, 2023 FDA approval of RYSTIGGO ® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive 1 U.S. FDA approval is based on the pivotal...

UCB y Veeva colaboran para mejorar la experiencia de los pacientes en los ensayos clínicos PR Newswire BRUSELAS y PLEASANTON, California, 23 de mayo de 2023 Las empresas colaboran para establecer un nuevo estándar de ensayos clínicos digitales centrados en el paciente BRUSELAS y PLEASANTON, California , 23 de mayo de 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) y UCB , una compañía biofarmacéutica global, han anunciado hoy una colaboración que se centrará en soluciones tecnológicas...

UCB et Veeva collaborent pour améliorer l'expérience des patients dans les essais cliniques PR Newswire BRUXELLES et PLEASANTON, Californie, 23 mai 2023 Les entreprises collaborent pour établir une nouvelle norme en matière d'essais cliniques numériques centrés sur le patient BRUXELLES et PLEASANTON, Californie , 23 mai 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) et UCB , une société biopharmaceutique mondiale, ont annoncé aujourd'hui une collaboration qui se concentrera sur des...

UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials PR Newswire BRUSSELS and PLEASANTON, Calif., May 23, 2023 Companies collaborate to set a new standard for patient-centric digital clinical trials BRUSSELS and PLEASANTON, Calif. , May 23, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and UCB , a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial...

UCB und Veeva arbeiten zusammen, um die Patientenerfahrung in klinischen Studien zu verbessern PR Newswire BRÜSSEL und PLEASANTON, Kalifornien, 23. Mai 2023 Unternehmen arbeiten zusammen, um einen neuen Standard für patientenorientierte digitale klinische Studien zu setzen BRÜSSEL und PLEASANTON, Kalifornien , 23. Mai 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) und UCB , ein weltweit tätiges biopharmazeutisches Unternehmen, gaben heute ihre Zusammenarbeit bekannt, die sich auf...

UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials PR Newswire BRUSSELS and PLEASANTON, Calif., May 23, 2023 Companies collaborate to set a new standard for patient-centric digital clinical trials BRUSSELS and PLEASANTON, Calif. , May 23, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and UCB , a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial...

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer PR Newswire BERLIN and BRUSSELS, May 11, 2023 UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum's discovery of treatments for solid tumors Ariceum's expertise in radiopharmaceuticals and labelling technology will aid UCB's discovery of treatments for immune-related...

Huma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis PR Newswire NEW YORK and LONDON, April 26, 2023 Project aims to improve patient outcomes through better clinical management of disease exacerbations using self-reported data Exciting opportunity to improve education and empowerment and for patients to be active participants in their own care Huma's EU MDR Class IIb regulated Software as Medical Device technology will advance...

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting PR Newswire BRUSSELS and ATLANTA, April 20, 2023 New insights from leading portfolio demonstrate ongoing commitment to improving outcomes and experiences of those living with epilepsy and rare epileptic syndromes Data will showcase further insights into the potential of UCB's generalized myasthenia gravis (gMG) pipeline UCB will also host an industry sponsored therapeutic update...

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance PR Newswire ATLANTA, April 17, 2023 ATLANTA , April 17, 2023 /PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final rule stating that FINTEPLA oral solution is no longer subject to the Controlled Substances Act (CSA). This change is immediate. The DEA rule means all...

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks PR Newswire BRUSSELS and ATLANTA, March 18, 2023 Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements over placebo in signs and symptoms of hidradenitis suppurativa at week 16, as measured by HiSCR50 Bimekizumab demonstrated deep levels of clinical response over placebo...